Last reviewed · How we verify

FTC-TDF PrEP

University of Washington · FDA-approved active Small molecule

FTC-TDF PrEP blocks reverse transcriptase in HIV, preventing the virus from converting its RNA genome into DNA and integrating into host cells.

FTC-TDF PrEP blocks reverse transcriptase in HIV, preventing the virus from converting its RNA genome into DNA and integrating into host cells. Used for HIV pre-exposure prophylaxis (PrEP) in high-risk individuals.

At a glance

Generic nameFTC-TDF PrEP
SponsorUniversity of Washington
Drug classNucleoside/nucleotide reverse transcriptase inhibitor combination
TargetHIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

Emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) are nucleoside/nucleotide reverse transcriptase inhibitors that work synergistically to suppress HIV replication. When taken as pre-exposure prophylaxis (PrEP), they maintain sufficient drug levels in blood and tissues to block HIV infection at the point of viral entry and early replication, reducing transmission risk in high-risk individuals.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results